Variant report
Variant | nsv581825 |
---|---|
Chromosome Location | chr2:49604892-49639121 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs817019 | chr2:49604892-49604893 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
2 | rs185096373 | chr2:49604896-49604897 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs561115669 | chr2:49605010-49605011 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs544919224 | chr2:49605012-49605013 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs554544285 | chr2:49605075-49605076 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs532941940 | chr2:49605079-49605080 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs150217447 | chr2:49605089-49605090 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs549910062 | chr2:49605099-49605100 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs374033370 | chr2:49605117-49605118 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs372881556 | chr2:49605190-49605191 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs182214852 | chr2:49610001-49610002 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
12 | rs117555627 | chr2:49610004-49610005 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
13 | rs540918329 | chr2:49610007-49610008 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
14 | rs141611095 | chr2:49610011-49610012 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
15 | rs371830543 | chr2:49610025-49610026 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
16 | rs142970353 | chr2:49610029-49610030 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
17 | rs564662145 | chr2:49610032-49610033 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
18 | rs576559451 | chr2:49610045-49610046 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
19 | rs374069682 | chr2:49610068-49610069 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
20 | rs368934413 | chr2:49610114-49610115 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
21 | rs147067546 | chr2:49610125-49610126 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
22 | rs558422222 | chr2:49610156-49610157 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
23 | rs185950306 | chr2:49610172-49610173 | Active TSS | n/a | n/a | Overlapped CNVs | n/a |
24 | rs817027 | chr2:49610186-49610187 | Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
25 | rs527841834 | chr2:49610232-49610233 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
26 | rs540813525 | chr2:49610241-49610242 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
27 | rs551509233 | chr2:49610278-49610279 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
28 | rs190926100 | chr2:49610280-49610281 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
29 | rs533779519 | chr2:49610296-49610297 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
30 | rs548851816 | chr2:49610309-49610310 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
31 | rs567254727 | chr2:49610327-49610328 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
32 | rs17038643 | chr2:49610339-49610340 | Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
33 | rs557084208 | chr2:49610366-49610367 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
34 | rs817028 | chr2:49610368-49610369 | Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
35 | rs547497142 | chr2:49610390-49610391 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
36 | rs182605147 | chr2:49610393-49610394 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
37 | rs138440031 | chr2:49610433-49610434 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
38 | rs375077668 | chr2:49610450-49610451 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
39 | rs17038649 | chr2:49610479-49610480 | Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
40 | rs562341446 | chr2:49610481-49610482 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
41 | rs557410224 | chr2:49610524-49610525 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
42 | rs187343347 | chr2:49610576-49610577 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
43 | rs141047506 | chr2:49610605-49610606 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs577363347 | chr2:49610617-49610618 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs150268505 | chr2:49610645-49610646 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs562348838 | chr2:49610667-49610668 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs190608676 | chr2:49610669-49610670 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs115178127 | chr2:49610694-49610695 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs560230554 | chr2:49610722-49610723 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs559633428 | chr2:49610809-49610810 | Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Medulloblastoma | 21979893 | CNVD |
Lynch syndrome | 18415027 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
Ovarian neoplasms | 16753589 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Adrenal tumor | 17535989 | CNVD |
Breast cancer | 21264507 | CNVD |
Basal cell lymphoma | 17053054 | CNVD |
Medulloblastoma | 17522785 | CNVD |
Cancer | 23418310 | CNVD |
Breast cancer | 17603634 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ependymoma | 16718352 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Prostate cancer | 18632612 | CNVD |
Bladder cancer | 21909424 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Intellectual disability | 22102821 | CNVD |
Cancer | 20164919 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
Autism | 17483303 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Esophageal adenocarcinoma | 18519675 | CNVD |
Medulloblastoma | 20607354 | CNVD |
Leukemia | 18628472 | CNVD |
Autism | 22495311 | CNVD |
Autism | 18522746 | CNVD |
Breast cancer | 21785460 | CNVD |
Lung cancer | 18438408 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Neuroblastoma | 21508638 | CNVD |
Neurodevelopmental disorder | 22521361 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
Colorectal cancer | 16272173 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Williams Syndrome | 20824207 | CNVD |
Breast cancer | 16272173 | CNVD |
Lung cancer | 17297452 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Ovarian cancer | 21720365 | CNVD |
abnormal development | 18461090 | CNVD |
Breast cancer | 21364760 | CNVD |
Schizophrenia | 20433910 | CNVD |
Autism | 21701786 | CNVD |
Attention deficit hyperactivity disorder | 21324949 | CNVD |
Austim spectrum disorder | 21302340 | CNVD |
Schizophrenia | 20587603 | CNVD |
Schizophrenia | 20553308 | CNVD |
Autism | 22241247 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Lung adenocarcinoma | 17086460 | CNVD |
Retinoblastoma | 22278416 | CNVD |
Cancer | 21183584 | CNVD |
Breast cancer | 16397240 | CNVD |
Acute lymphoblastic leukemia | 18768390 | CNVD |
Mental retardation | 19521722 | CNVD |
Schizophrenia | 18990708 | CNVD |
Schizophrenia | 18940311 | CNVD |
Schizophrenia | 19348701 | CNVD |
Schizophrenia | 18945720 | CNVD |
Schizophrenia | 19571808 | CNVD |
Prostate cancer | 16573809 | CNVD |
Neuroticism | 17667963 | CNVD |
Schizophrenia | 19443537 | CNVD |
Schizophrenia | 19546859 | CNVD |
Autism | 17322880 | CNVD |
Lung cancer | 17086460 | CNVD |
Chronic lymphocytic leukemia | 17053054 | CNVD |
Hereditary non-polyposis colorectal cancer | 19566914 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Pancreatic ductal adenocarcinoma | 19077451 | CNVD |
Basal cell lymphoma | 21115979 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:49604200-49605200 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
2 | chr2:49610000-49610200 | Active TSS | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
3 | chr2:49610200-49610600 | Flanking Active TSS | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
4 | chr2:49610600-49610800 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
5 | chr2:49610800-49611000 | Flanking Active TSS | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
6 | chr2:49611000-49611200 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
7 | chr2:49627400-49627600 | Enhancers | Brain Germinal Matrix | brain |
8 | chr2:49628800-49629000 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
9 | chr2:49629200-49630800 | Weak transcription | ES-UCSF4 Cell Line | embryonic stem cell |
10 | chr2:49630000-49631600 | Enhancers | Brain Germinal Matrix | brain |
11 | chr2:49630400-49631200 | Enhancers | H1 Cell Line | embryonic stem cell |
12 | chr2:49630400-49631400 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
13 | chr2:49630400-49632400 | Enhancers | HUES48 Cell Line | embryonic stem cell |
14 | chr2:49630600-49632000 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
15 | chr2:49630600-49632200 | Enhancers | HUES64 Cell Line | embryonic stem cell |
16 | chr2:49630600-49632200 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
17 | chr2:49630800-49631600 | Enhancers | HUES6 Cell Line | embryonic stem cell |
18 | chr2:49630800-49632000 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
19 | chr2:49630800-49632000 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
20 | chr2:49631200-49631600 | Weak transcription | H1 Cell Line | embryonic stem cell |
21 | chr2:49631400-49631800 | Flanking Active TSS | iPS-20b Cell Line | embryonic stem cell |
22 | chr2:49631600-49632000 | Enhancers | H1 Cell Line | embryonic stem cell |
23 | chr2:49631800-49632000 | Enhancers | iPS-20b Cell Line | embryonic stem cell |